Ixabepilone for the treatment of solid tumors: a review of clinical data.

Article Details

Citation

Copy to clipboard

Denduluri N, Swain SM

Ixabepilone for the treatment of solid tumors: a review of clinical data.

Expert Opin Investig Drugs. 2008 Mar;17(3):423-35. doi: 10.1517/13543784.17.3.423 .

PubMed ID

18321240 [ View in PubMed

]

Abstract

BACKGROUND: Microtubule stabilizing agents such as taxanes are an integral part of therapy for multiple solid tumors. However, due to limitations of these agents, newer more effective cytotoxic agents are necessary. Ixabepilone, an epothilone B analog, is a novel microtubule stabilizing agent. OBJECTIVE: This review provides an updated summary of emerging clinical experience with Ixabepilone. METHODS: Phase I, II and III clinical trials presented in abstract form or journal articles found within a PubMed search through November 2007 are described in this review. RESULTS/CONCLUSION: Ixabepilone offers promising clinical activity in a variety of solid tumors. Ixabepilone is FDA-approved for the treatment of breast cancer refractory to anthracyclines and taxanes. The optimal dose and schedule are still being defined, and the predominant side effects are bone marrow suppression and neuropathy.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Ixabepilone	Tubulin beta-3 chain	Protein	Humans	Yes	Inhibitor	Details